Free practice quiz
BCPMP Prep Course (BCPMP): free quiz
10 questions from the program. See your score right away, then unlock the explanation of every answer.
- Question 1 of 10
A 58-year-old adult with diabetes reports burning, electric pain in both feet for 6 months, worse at night, with allodynia to bedsheets. Current medications include acetaminophen 650 mg by mouth every 8 hours, ibuprofen 400 mg by mouth three times daily as needed, sertraline 100 mg by mouth daily, and metformin 1000 mg by mouth twice daily. eGFR is 38 mL/min/1.73 m2. As the clinical pharmacist, which mechanism-based medication strategy is most appropriate to recommend?
Why B is correct
Burning, electric pain with allodynia suggests peripheral neuropathic pain rather than primarily inflammatory nociception. Duloxetine enhances descending serotonergic and noradrenergic inhibition and is guideline-supported for painful diabetic neuropathy. With eGFR 38 mL/min/1.73 m2, duloxetine may be used; avoidance is generally emphasized when CrCl is below 30 mL/min. Concomitant sertraline requires interaction awareness, so the pharmacist should recommend switching rather than combining serotonergic antidepressants.
Pharmacist Action: NOTICE neuropathic descriptors and CKD. SAY to the prescriber that neuropathic features support an SNRI, but sertraline overlap needs a planned transition. MONITOR pain relief, sedation, blood pressure, and serotonin-toxicity symptoms within 2 to 4 weeks. HOLD/CLARIFY combining duloxetine with sertraline unless a cross-taper plan is specified; ESCALATE if severe adverse effects occur.
Why A is incorrect
It is tempting because ibuprofen can help painful inflammatory states. The eliminating fact is that neuropathic features such as allodynia and burning pain respond poorly to NSAID escalation, and scheduled high-dose NSAIDs increase kidney and gastrointestinal risk in CKD. Guideline-based management favors neuropathic agents over NSAID intensification here.
Pharmacist Action: NOTICE the mismatch between symptom pattern and anti-inflammatory escalation. SAY that higher-dose ibuprofen offers limited neuropathic benefit and adds renal risk. MONITOR serum creatinine, blood pressure, and GI toxicity if NSAIDs are used. HOLD/CLARIFY chronic scheduled NSAID escalation in CKD.
Why C is incorrect
It is tempting because tramadol has dual opioid and monoaminergic activity and may appear useful for mixed pain. The eliminating fact is that tramadol combined with sertraline raises serotonin syndrome and seizure risk, and opioids are not preferred first-line therapy for chronic painful diabetic neuropathy. The interaction is the key discriminator.
Pharmacist Action: NOTICE the serotonergic interaction trap. SAY that tramadol plus sertraline increases serotonin-toxicity risk and should generally be avoided. MONITOR for agitation, diaphoresis, tremor, and mental-status changes if exposure occurs. HOLD/CLARIFY this combination before dispensing.
Why D is incorrect
It is tempting because pregabalin is also evidence-based for neuropathic pain. The eliminating fact is the dose: with eGFR about 38 mL/min/1.73 m2, 75 mg three times daily is too high as an initial renally adjusted regimen. This is the dose-adjustment trap; lower total daily dosing is recommended in reduced kidney function.
Pharmacist Action: NOTICE that the agent is reasonable but the renal dose is not. SAY that pregabalin requires dose reduction at this kidney function. MONITOR dizziness, edema, and renal function during titration. HOLD/CLARIFY pregabalin orders that exceed renal-adjusted starting doses.
Review Neuropathic pain mechanism-based selection — focus on symptom descriptors, serotonergic interactions, and renal dose adjustment rules.
- Question 2 of 10
A patient with chronic pain reports that previous medication trials targeting local inflammation did not improve function. The pharmacist suspects a nociplastic component and is asked what treatment goal should be emphasized. Which goal best matches the source pack?
A. This is correct because the source pack states that nociplastic pain often requires multimodal and functional goals. Function is therefore a key treatment target in this classification.
B. This is incorrect because the source pack associates opioid strategies with nociceptive pain and does not define nociplastic pain as purely nociceptive.
C. This is incorrect because TCAs are listed as adjuvant agents favored for neuropathic pain, while nociplastic pain is described as requiring multimodal and functional goals.
D. This is incorrect because the source pack supports functional goals for nociplastic pain; classification should inform, not replace, functional assessment and care planning.
- Question 3 of 10
A patient has acute dental pain after a procedure. The pharmacist confirms the likely source, assesses pain severity, recommends an initial plan, and asks the patient to report whether pain improves over the next day. Which concept is most directly illustrated?
A. This is incorrect because the case describes an acute pain state, and the source pack specifically emphasizes cause, severity, and short-term reassessment for acute pain management.
B. This is correct because the pharmacist considers the cause, assesses severity, and plans short-term reassessment, exactly matching the acute pain principle in the source pack.
C. This is incorrect because the source pack states that duration alone does not define treatment intensity or risk.
D. This is incorrect because escalation is required when the presentation suggests instability or a nonpharmacotherapy emergency, not for all postprocedural pain.
- Question 4 of 10
A patient reports chronic knee pain, difficulty rising from a chair, and concern about kidney problems. Which pharmacist assessment priority best matches the source pack?
A. This is correct because difficulty rising from a chair reflects function and mobility, which are key monitoring targets. Kidney problems also matter because NSAID selection depends on renal risk.
B. This is incorrect because the source pack states that NSAID selection depends on renal risk. Recommending oral NSAID therapy without reviewing kidney history is inconsistent with that principle.
C. This is incorrect because chair-rise difficulty is a functional limitation. The source pack specifically highlights function and mobility as key monitoring targets.
D. This is incorrect because osteoarthritis, low back pain, and inflammatory syndromes differ in mechanism and treatment goals. The source pack does not support assuming identical mechanisms.
- Question 5 of 10
A hospice nurse calls about a patient with cancer pain who has acceptable baseline relief but repeated brief pain flares before the next scheduled dose. Which pharmacist task from the supplied source pack is most relevant?
A. Correct. The node lists breakthrough dosing as a common pharmacist task in cancer palliative and end-of-life pain.
B. Incorrect. The selected node is specifically about cancer palliative and end-of-life pain, where goals shift toward comfort and rapid relief.
C. Incorrect. Recurrent flares suggest the need to address breakthrough pain rather than leaving the regimen unchanged.
D. Incorrect. The source pack emphasizes comfort and rapid relief in this setting, not prioritizing diagnostic testing over symptom control.
- Question 6 of 10
Which patient statement most clearly provides information about pain location?
A. Burning describes quality, not location. B. This is correct because it specifies where the pain occurs, which is the location component of symptom presentation. C. Worst at night describes timing, not location. D. Difficulty climbing stairs describes functional impact, not location.
- Question 7 of 10
Which care-plan element most directly operationalizes the source pack statement that care plans should incorporate patient values and barriers?
A. This is incorrect because it is clinician-centered and does not incorporate patient values. The source emphasizes patient-centered communication and care planning around values and barriers.
B. This is correct because functional priorities, treatment concerns, and access barriers directly reflect patient values and barriers. Including them supports a biopsychosocial care plan.
C. This is incorrect because it morally frames uncontrolled symptoms. The source specifically discourages moral framing of uncontrolled symptoms.
D. This is incorrect because sleep, mood, and social stressors affect pain outcomes and should not be excluded when relevant.
- Question 8 of 10
A 29-year-old patient presents to the ambulatory pharmacy asking for advice about worsening heartburn. Current medications are omeprazole 20 mg by mouth daily, calcium carbonate 500 mg by mouth as needed, sertraline 50 mg by mouth daily, and ibuprofen 600 mg by mouth three times daily for 2 weeks after a sports injury. The patient reports black stools, dizziness, and fatigue for 2 days. As the pharmacist collecting assessment information before recommending therapy, what is the most appropriate next action?
Why A is correct
Black stools, dizziness, and fatigue are red flags for possible upper gastrointestinal bleeding, and ibuprofen 600 mg three times daily is a relevant precipitating exposure despite concurrent omeprazole. The pharmacist should recognize this as unsafe for pharmacist-only symptomatic management, advise holding the NSAID, and urgently escalate for medical evaluation rather than simply intensifying acid suppression.
NOTICE: melena, dizziness, fatigue, and recent high-dose NSAID use. SAY: “These symptoms may indicate gastrointestinal bleeding and need urgent evaluation today.” MONITOR: hemodynamic symptoms and medication exposure history immediately. HOLD/CLARIFY/ESCALATE: hold ibuprofen and escalate at once when melena or symptomatic blood loss is reported.
Why B is incorrect
This is tempting because persistent reflux symptoms may warrant PPI dose escalation. The eliminating fact is that melena and dizziness suggest bleeding, not uncomplicated acid breakthrough; delaying evaluation by increasing omeprazole risks harm. Guidelines for dyspepsia and GI bleeding prioritize urgent assessment when alarm features are present.
NOTICE: alarm symptoms override routine GERD step-up therapy. SAY: do not self-manage suspected bleeding with a dose increase alone. MONITOR: symptom chronology and NSAID exposure. HOLD/CLARIFY/ESCALATE: escalate immediately if black stools or presyncope occur.
Why D is incorrect
This is tempting because famotidine is a reasonable acid-suppressive alternative. The eliminating fact is that changing to an H2RA does not address suspected active GI bleeding and would provide less potent acid suppression than high-dose PPI therapy used in bleeding pathways. Alarm features require urgent referral, not outpatient substitution.
NOTICE: a drug-switch option may seem conservative but misses the red flag. SAY: symptom severity suggests possible bleeding rather than routine reflux. MONITOR: ongoing stool color changes and dizziness. HOLD/CLARIFY/ESCALATE: refer urgently instead of changing to famotidine.
Why C is incorrect
This is tempting because sucralfate offers mucosal protection for upper GI symptoms. The eliminating fact is that sucralfate can mask symptoms without addressing possible hemorrhage, and continued NSAID exposure is unsafe. In addition, the key drug-related problem is probable NSAID toxicity requiring cessation and urgent evaluation, not adjunctive outpatient symptom treatment.
NOTICE: continuing the offending NSAID is the major safety error. SAY: avoid further ibuprofen until a clinician evaluates possible bleeding. MONITOR: worsening weakness, syncope, or persistent melena. HOLD/CLARIFY/ESCALATE: stop NSAID and escalate same day.
Review Red flags requiring escalation beyond pharmacist-only management — focus on alarm GI bleeding symptoms and NSAID-related harm.
- Question 9 of 10
A patient tells the pharmacist, I feel like the team does not believe me when I describe my pain. Which response best uses NURSE by naming the emotion?
A. This is correct because it explicitly names the patient's apparent emotion and supports an empathic response to an emotion-laden encounter.
B. This explains the team's process but does not name or respond to the patient's emotion.
C. This prioritizes assessment workflow over empathy and may reduce engagement.
D. This redirects the concern elsewhere and does not use the pharmacist communication skills emphasized in the source pack.
- Question 10 of 10
A patient states, I need someone to tell me exactly what is going to happen with my illness before I decide about this medication. The pharmacist recognizes that the patient also needs medication counseling. What is the best next step?
A. This is incorrect because giving prognosis and deciding the patient's goals exceeds the pharmacist role described in the source pack.
B. This is correct because it combines medication implication counseling with escalation of prognosis discussion to the broader team and recognizes the patient's concern.
C. This is incorrect because documentation should capture concerns, education, and follow-up needs.
D. This is incorrect because the pharmacist can still clarify medication implications within scope while coordinating unresolved prognosis questions with the team.
See why each answer is right or wrong
Enter your email to unlock the explanation of every question, free.